Maryland’s prescription drug affordability board (PDAB) passed resolutions affirming that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) carry ...

SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not thrombosis among patients with type 2 diabetes.

After months of deliberation, information gathering and public testimony, a state board unanimously agreed Monday that two common medications for type-2 diabetes and other conditions appear to pose an ...